JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M105607200 on September 10, 2001

J. Biol. Chem., Vol. 276, Issue 45, 41841-41849, November 9, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/45/41841    most recent
M105607200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McGuire, J.
Right arrow Articles by Poellinger, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McGuire, J.
Right arrow Articles by Poellinger, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Definition of a Dioxin Receptor Mutant That Is a Constitutive Activator of Transcription

DELINEATION OF OVERLAPPING REPRESSION AND LIGAND BINDING FUNCTIONS WITHIN THE PAS DOMAIN*

Jacqueline McGuireDagger , Kensaku OkamotoDagger , Murray L. Whitelaw§, Hirotoshi Tanaka, and Lorenz PoellingerDagger ||

From the Dagger  Department of Cell and Molecular Biology, Medical Nobel Institute, Karolinska Institute, S-171 77 Stockholm, Sweden, the § Department of Biochemistry, University of Adelaide, Adelaide, South Australia 5005, Australia, and the  Division of Clinical Immunology, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan

Received for publication, June 18, 2001, and in revised form, September 6, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The intracellular dioxin (aryl hydrocarbon) receptor is a ligand-activated transcription factor that mediates the adaptive and toxic responses to environmental pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin and structurally related congeners. Whereas the ligand-free receptor is characterized by its association with the molecular chaperone hsp90, exposure to ligand initiates a multistep activation process involving nuclear translocation, dissociation from the hsp90 complex, and dimerization with its partner protein Arnt. In this study, we have characterized a dioxin receptor deletion mutant lacking the minimal ligand-binding domain of the receptor. This mutant did not bind ligand and localized constitutively to the nucleus. However, this protein was functionally inert since it failed to dimerize with Arnt and to bind DNA. In contrast, a dioxin receptor deletion mutant lacking the minimal PAS B motif but maintaining the N-terminal half of the ligand-binding domain showed constitutive dimerization with Arnt, bound DNA, and activated transcription in a ligand-independent manner. Interestingly, this mutant showed a more potent functional activity than the dioxin-activated wild-type receptor in several different cell lines. In conclusion, the constitutively active dioxin receptor may provide an important mechanistic tool to investigate receptor-mediated regulatory pathways in closer detail.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The intracellular dioxin receptor also known as the aryl hydrocarbon receptor, is a ligand-dependent transcription factor that mediates the biological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),1 commonly known as dioxin (1). Although disruption of the dioxin receptor gene in mice has not yielded conclusive results, it remains a possible scenario that physiological mechanisms may exist for activation of receptor function, e.g. during critical stages of vertebrate development (2-5). However, an endogenous ligand for the receptor has not yet been identified, suggesting that alternative pathways for receptor activation may exist.

In the absence of ligand, the dioxin receptor is generally found in the cytoplasm associated in high molecular weight complexes comprising a dimer of the molecular chaperone hsp90, an immunophilin homolog known as XAP2 (hepatitis B virus X-associated protein-2)/AIP (aryl hydrocarbon receptor-interacting protein)/ARA9 (aryl hydrocarbon receptor-associated protein-9), and the co-chaperone p23 (6-11). In the presence of dioxin, the receptor is converted to a functional DNA-binding species in a multistep process involving nuclear translocation, dissociation from the hsp90 complex, and dimerization with its partner protein Arnt (Ah receptor nuclear translocator). Formation of the dioxin receptor/Arnt heterodimer is a prerequisite for DNA binding and promotes transcription of target genes including those encoding xenobiotic-metabolizing enzymes such as CYP1A1 (1). Both the dioxin receptor and Arnt are members of a distinct subclass of the basic helix-loop-helix (bHLH) family of transcriptional regulators known as bHLH/PAS proteins. Members of this potent subfamily mediate diverse biological processes, including response to hypoxia, circadian rhythmicity, and development of the central nervous system (1, 12, 13). Contiguous to the amino-terminal bHLH DNA-binding and dimerization motifs, members of this subfamily are identified on the basis of a second region of homology, the PAS (Per-Arnt-Sim) domain, originally identified in the Drosophila proteins PER and SIM, and Arnt. The PAS domain encompasses a region of ~250-300 amino acids harboring two degenerate repeat sequences of 44 amino acids termed PAS A and PAS B, respectively, and has been shown to constitute an additional dimerization interface that can function independently of the bHLH motif (14, 15). More recently, additional roles in the regulation of heterodimerization and DNA binding specificities have been attributed to the PAS domain (16, 17). In the case of the dioxin receptor, the carboxyl-terminal half of the PAS domain, spanning the hydrophobic PAS B repeat motif, has been shown to harbor the core ligand-binding activity of the receptor (18, 19). In addition to binding ligand, this region has also been shown to mediate association with the molecular chaperone hsp90 (19), consistent with a role for hsp90 in regulating signal responsiveness by folding the ligand-binding domain (LBD) into a high affinity ligand binding conformation (20-22). Taken together, the PAS domain appears to be a complex structure harboring a number of distinct functional activities.

In our efforts to understand further the complex interplay between structure and function of the dioxin receptor, we have examined the functional activity of a dioxin receptor deletion mutant lacking the core LBD. Although this protein is constitutively localized to the nucleus, it was functionally inert on a xenobiotic response element (XRE)-driven reporter gene both in the presence and absence of ligand. In contrast, deletion of amino acids 288-421 encompassing the minimal PAS B motif generated an activated form of the receptor that stimulated transcription in the absence of ligand, demonstrating that this mutant functions as a constitutively active regulatory protein. Interestingly, this mutant showed a more potent functional activity than the dioxin-activated wild-type receptor, possibly indicating that exposure to ligand does not induce maximal activation of the receptor.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmid Constructions-- The plasmids used for in vitro translation of the full-length dioxin receptor (mDR/ATG/pSP72) and Arnt (Arnt/pGem) have been described previously (23, 24). For construction of the dioxin receptor deletion mutants DRDelta LBD and DRDelta PASB, pSportAhR containing full-length murine dioxin receptor cDNA (18) was amplified by PCR using primers designed to yield fragments of the dioxin receptor encoding codons 1-229 and 1-287, respectively. Primers were designed to carry restriction sites for ClaI and XhoI, enabling directional insertion into ClaI/XhoI-digested pGem7 to give pDR1-229/Gem and pDR1-287/Gem, respectively. A dioxin receptor fragment encompassing codons 422-805 was obtained by PCR from pSportAhR using specific primers carrying restriction sites for XhoI. The resulting fragment was digested with XhoI and subcloned into XhoI-digested pDR1-229/Gem and pDR1-287/Gem to give pDRDelta LBD/Gem and pDRDelta PASB/Gem, respectively. Whenever possible, PCR sequence was replaced by natural dioxin receptor sequences from mDR/ATG/pSP72 (23). All constructs were confirmed by DNA sequence analysis. ClaI/XbaI digestion of the corresponding pDR/Gem constructs followed by subcloning into ClaI/XbaI-digested eukaryotic expression plasmid pCMV4 yielded constructs pDRDelta LBD/CMV4 and pDRDelta PASB/CMV4. The FLAG-tagged expression constructs pDR-FLAG/CMV4 and pDRDelta PASB-FLAG/CMV4 were constructed by incorporating a FLAG tag epitope (Sigma), produced by PCR, at the extreme 3'-end of the coding sequence of the respective cDNAs. The pCMX-SAH/Y145F expression vector, encoding a modified and highly chromophoric form of green fluorescent protein (GFP) under the control of the cytomegalovirus promoter, has been described previously (25). To create a GFP fusion construct of the full-length dioxin receptor for expression and visualization in living cells, a PCR fragment was amplified from pSportAhR using primers designed to yield a fragment of the dioxin receptor encoding codons 1-287. Primers were designed to carry restriction sites for BamHI and NheI, enabling in-frame directional insertion into BamHI/NheI-digested pCMX-SAH/Y145F. A CelII/XbaI dioxin receptor fragment encompassing amino acids 72-805 isolated from mDR/ATG/pSP72 was then inserted to provide the final construct pGFP-mDR/CMX. GFP fusion constructs for DRDelta LBD and DRDelta PASB were produced by digesting pGFP-mDR/CMX with CelII/NotI and replacing with CelII/NotI fragments isolated from pDRDelta LBD/Gem and pDRDelta PASB/Gem, thereby producing pGFP-DRDelta LBD/CMX and pGFP-DRDelta PASB/CMX, respectively. To produce the GFP fusion construct containing the minimal LBD of the dioxin receptor, a PCR fragment encoding codons 230-421 was amplified from pSportAhR. The primers were designed to carry restriction sites for XhoI, enabling insertion into SalI-digested pCMX-SAH/Y145F to give pGFP-DRLBD/CMX. pGRDBD/CMV4 and pGRDBDmDR/CMV4 (previously referred to as pGRDBDmDR83-805/CMV4) have been described (26). To construct the glucocorticoid receptor/mouse dioxin receptor deletion constructs for expression in mammalian cells, a ClaI/XbaI fragment was isolated from pDRDelta LBD/Gem and pDRDelta PASB/Gem and subcloned into ClaI/XbaI-digested pGRDBD/CMV4 to give pGRDBD/DRDelta LBD/CMV4 and pGRDBD/DRDelta PASB/CMV4, respectively. The yeast expression vectors pGRDBD/2HG and pGRDBDmDR/2HG (previously referred to as pGRDBDmDR83-805/2HG) have been described (22). To construct the glucocorticoid receptor/mouse dioxin receptor deletion constructs for expression in yeast, an NcoI fragment was isolated from pDRDelta LBD/Gem and pDRDelta PASB/Gem and subcloned into NcoI-digested pGRDBDmDR/2HG to give pGRDBD/DRDelta LBD/2HG and pGRDBD/DRDelta PASB/2HG, respectively. The mammalian reporter gene constructs pTX.DIR and p(GRE)2T105LUC and the yeast reporter plasmid pUCDelta SS26X have been described previously (27-29).

Cell Culture and Transient Transfection Assays-- CHO cells were grown in Ham's F-12 medium, and HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 10% fetal calf serum, 100 IU of penicillin, and 100 mg/ml streptomycin (Life Technologies, Inc.). For reporter gene assays, cells were transiently transfected with 2 µg of reporter plasmid and 1 µg of expression plasmids using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's recommendations. After a 6-h transfection period, cells were induced either with 10 nM TCDD (Cambridge Isotope Laboratories) or with an equivalent volume of vehicle (Me2SO) alone. Following incubation for 48 h, cells were collected and washed with PBS; extracts were prepared; and luciferase activity was measured. Experiments were carried out in duplicate, and extracts were normalized for protein concentration. For immunoblot analysis, transfected CHO cells were collected, washed with PBS, and lysed in 50 µl of whole cell extract buffer (20 mM Hepes, pH 7.9, 1.5 mM MgSO4, 0.2 mM EDTA, 0.42 M NaCl, 0.5% (v/v) Nonidet P-40, 25% (v/v) glycerol, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride) on ice for 30 min. Following centrifugation, the resulting supernatants were used as whole cell extracts. Samples containing 30 µg of protein were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and electroblotted onto nitrocellulose membranes. Immunodetection was achieved by incubation with mouse monoclonal anti-FLAG antibodies (Sigma), followed by chemiluminescence using the ECL detection system (Amersham Pharmacia Biotech).

Yeast Strains, Transformations, and beta -Galactosidase Assays-- The yeast strain GRS4 has been described previously (29). Transformation of GRS4 with expression plasmids for the indicated glucocorticoid receptor/dioxin receptor fusion proteins together with the reporter plasmid pUCDelta SS26X was carried out using a modification of the lithium acetate method (30). Quantitation of beta -galactosidase reporter gene activity in GRS4 transformants was carried out as described previously (22).

Subcellular Localization Assay Using GFP Fusion Proteins-- CHO cells were grown on poly-D-lysine-coated sterile coverslips in 35-mm diameter dishes and transiently transfected with 1 µg of each expression plasmid for GFP fusion proteins using 2 µl of FuGENE 6 transfection reagent (Roche Molecular Biochemicals) per dish. After a 6-h incubation, the medium was replaced with fresh medium, and incubation was continued for a further 24 h. The cells were then treated with 10 nM TCDD or vehicle (Me2SO) for 2 h, washed twice with PBS, and fixed with 4% paraformaldehyde in PBS for 15 min at room temperature. After three washes with PBS, the cells were quickly rinsed with deionized water and mounted on glass slides using Gel/Mount (Biomeda Co. Ltd.). Subcellular localization of GFP fusion proteins was observed with a Leica DMRXA fluorescent microscope using the GFP filter set, and images were scanned with a Hamamatsu digital camera, processed with OpenLab Version 3.0 software, and exported as composite PICT files. For each construct and each condition, ~200 cells expressing GFP fusion proteins were observed, and representative images are presented. At least three independent experiments were carried out for each GFP fusion protein construct.

In Vitro Translation and Co-immunoprecipitation Experiments-- The wild-type dioxin receptor, the dioxin receptor deletion constructs DRDelta LBD and DRDelta PASB, and Arnt were translated in vitro in the presence or absence of [35S]methionine (Amersham Pharmacia Biotech) in rabbit reticulocyte lysate (Promega) according to the manufacturer's recommendations. For Arnt co-immunoprecipitation experiments, equal concentrations of the indicated in vitro translated, [35S]methionine-labeled proteins were incubated with in vitro translated, unlabeled Arnt (5 µl) in TEG buffer (20 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10% (w/v) glycerol, and 1 mM dithiothreitol) containing CompleteTM mini protease inhibitors (Roche Molecular Biochemicals) in the presence or absence of 10 nM TCDD (dioxin) either for 2 h at 25 °C or overnight at 4 °C in a final volume of 10 µl. Protein mixtures were then precleared by incubation on ice with 10 µl of preimmune serum for 15 min, followed by an additional 15-min incubation with 50 µl of a 50% slurry of protein A-Sepharose in TEG buffer supplemented with 150 mM NaCl, 0.2% Triton X-100, and 2 mg/ml bovine serum albumin. Following rapid centrifugation, the resulting supernatants were incubated with 10 µl of either anti-Arnt antiserum (24) or preimmune serum for 1 h at room temperature. Protein A-Sepharose was then added (50 µl of a 50% slurry in supplemented TEG buffer), and the samples were incubated on ice for a further 45 min. After brief centrifugation, Sepharose pellets were washed three times with 500 µl of supplemented TEG buffer, followed by a final wash with TEG buffer alone. Co-immunoprecipitated proteins were eluted by boiling in SDS sample buffer and analyzed by SDS-PAGE and chemiluminescence.

DNA Binding Assay-- DNA binding experiments were performed with in vitro translated, unlabeled Arnt together with the wild-type dioxin receptor or the dioxin receptor deletion mutants DRDelta LBD and DRDelta PASB as described previously (31). Briefly, equivalent concentrations of the indicated in vitro translated proteins were incubated with 10 µl of in vitro translated Arnt in the presence or absence of 10 nM TCDD for 2 h at 25 °C. DNA binding reactions were carried out by the addition of a 36-base pair 32P-labeled double-stranded oligonucleotide spanning the XRE1 motif of the rat CYP1A1 promoter (32) in 10 mM Hepes, 5% (v/v) glycerol, 0.05 mM dithiothreitol, 2.5 mM MgCl2, 1 mM EDTA, and 0.08% (w/v) Ficoll in a final volume of 40 µl containing 50 mM NaCl and 1 µg of poly(dI-dC) nonspecific competitor DNA (Amersham Pharmacia Biotech). Following incubation for 20 min at 25 °C, protein-DNA complexes were separated on a 4% low ionic strength native polyacrylamide gel (29:1 acrylamide/bisacrylamide) in Tris/glycine/EDTA buffer at 30 mA and analyzed by autoradiography.

Ligand Binding Assays-- Ligand binding assays were carried out essentially as described previously using a modified hydroxylapatite adsorption assay (21, 23). Briefly, equal concentrations of the in vitro translated, unlabeled wild-type dioxin receptor or the indicated dioxin receptor deletion mutants were made up to a final volume of 10 µl with blank reticulocyte lysate translation mixture, followed by dilution with 3 volumes of TEG buffer containing 2 mM dithiothreitol, 5 µg/ml protease inhibitor mixture (aprotinin, leupeptin, and pepstatin A), and 1 mM phenylmethylsulfonyl fluoride. The reaction mixtures were then incubated with 1 nM [3H]TCDD (40 Ci/mmol; Chemsyn, Lenexa, KS) in the presence or absence of a 150-fold molar excess of the specific competitor tetrachlorodibenzofuran at room temperature for 90 min. Following incubation, the reaction mixtures were treated with 50 µl of a 10% slurry (v/v) of dextran-coated charcoal in TEG buffer for 5 min on ice, followed by centrifugation. The resulting supernatants were then incubated with 50 µl of a 50% slurry (v/v) of hydroxylapatite in TEG buffer on ice for 30 min. Following rapid centrifugation, the supernatants were discarded, and the remaining pellets were washed four times with 500 µl of ice-cold TEG buffer containing 0.1% Tween 20. The pellets were eluted by incubating twice with 500 µl of ethanol, and the pooled supernatants were analyzed by scintillation counting.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A Dioxin Receptor Deletion Mutant Lacking the Minimal LBD Is Constitutively Localized to the Nucleus, but Is Functionally Inert-- In the absence of ligand, the dioxin receptor exists in the cytoplasm in a latent, non-DNA-binding form characterized by association with the heat shock protein hsp90. Exposure to ligand results in rapid nuclear accumulation of the receptor and conversion to a heterodimeric complex with Arnt, a form that is now competent to bind DNA and to initiate the transcription of target genes (1). Thus, the initial step in the activation of dioxin receptor function is binding of ligand. In addition to being a critical determinant of ligand-binding activity, the LBD of the dioxin receptor has also been postulated to be involved in the repression of a number of receptor activities that map outside the LBD itself such as dimerization with Arnt, DNA binding, and transcriptional activity (19, 26, 33). It has not yet been determined how the ligand-binding domain modulates this repressive activity. However, since hsp90 binding has been shown to colocalize within this region, it has been suggested that hsp90 itself may function as the agent of repression either by steric interference or by misfolding of adjacent structures (19, 22). We were interested to determine whether deletion of the minimal region of the dioxin receptor harboring the ligand- and hsp90-binding activities of the receptor would result in a protein that was uncoupled from regulation by dioxin. To this end, we have examined the functional activities, both in vitro and in vivo, of a dioxin receptor deletion mutant (DRDelta LBD) lacking the core-delineated LBD that is located between amino acids 230 and 421 (19, 21) and that spans the C-terminal half of the PAS domain of the mouse dioxin receptor (Fig. 1A). In control experiments, in vitro translation of DRDelta LBD in rabbit reticulocyte lysate resulted in a protein that had lost the ability to bind ligand, consistent with deletion of the minimal domain required for high affinity ligand binding of the dioxin receptor (data not shown). Furthermore, in a specific co-immunoprecipitation assay using monoclonal anti-hsp90 antibodies, this protein showed only low levels of interaction with hsp90 (data not shown) that were attributed to non-LBD interactions via the bHLH motif (31).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   A dioxin receptor deletion mutant lacking the minimal LBD is constitutively localized to the nucleus, but is functionally inert on an XRE-driven reporter gene in CHO cells. A, shown is schematic representation of the structural motifs within the full-length mouse dioxin receptor (mDR) and the dioxin receptor deletion mutant DRDelta LBD. B, shown is the subcellular distribution of GFP-dioxin receptor fusion proteins. CHO cells grown on glass coverslips were transiently transfected with 1 µg of each expression plasmid for the indicated dioxin receptor mutants fused to GFP. Twenty-four hours after transfection, the cells were treated with 10 nM TCDD or vehicle alone (0.1% Me2SO) for 2 h as indicated. Cells were then washed with PBS and fixed with 4% paraformaldehyde as described under "Experimental Procedures." Subcellular localization of the expressed GFP fusion proteins was observed using a Leica DMRXA fluorescent microscope with a GFP filter set. Approximately 200 cells were observed, and representative images are shown. The experiments were repeated at least three times for each GFP fusion construct with similar results. Original magnification was ×400. C, CHO cells were transiently transfected with the XRE-driven luciferase reporter gene pTX.DIR together with either the wild-type dioxin receptor or the dioxin receptor deletion mutant DRDelta LBD and Arnt. Following transfection, cells were treated with either 10 nM TCDD (black bars) or vehicle alone (0.1% Me2SO; shaded bars). The control lanes (CTRL) represent activity from the reporter alone and empty expression vector. Data are from one experiment performed in duplicate and are representative of three independent experiments.

A bipartite nuclear localization signal (NLS) has been identified in the N terminus of the dioxin receptor, incorporating basic residues within the DNA-binding domain of the bHLH motif. This single N-terminal NLS motif has been shown to be sufficient to mediate ligand-inducible nuclear import of the dioxin receptor in the context of the full-length protein (34). Using expression vectors carrying GFP fused in frame with either the full-length mouse dioxin receptor or the dioxin receptor deletion mutant DRDelta LBD, we examined the effect of deletion of the minimal LBD on intracellular localization of the dioxin receptor in living cells. In control experiments, transient transfection of CHO cells with the parental GFP construct alone revealed a uniform distribution of fluorescence throughout the cell that was unaffected by the presence of ligand (Fig. 1B). Transient expression of the GFP-dioxin receptor fusion construct resulted in a similar distribution as the parental GFP vector alone in untreated cells. As expected, upon exposure to ligand, fluorescence rapidly accumulated in the nuclear compartment of the cell (Fig. 1B) (34-36). In contrast, however, expression of the GFP-DRDelta LBD fusion construct showed constitutive nuclear localization in CHO cells even in the absence of ligand (Fig. 1B). Thus, deletion of the minimal LBD was sufficient to unmask the potent constitutive NLS activity contained within the remaining structure of the receptor. Furthermore, expression of a GFP fusion construct containing the minimal LBD of the dioxin receptor encompassing amino acids 230-421 resulted in constitutive cytoplasmic fluorescence that was unaffected by the addition of ligand (Fig. 1B). Taken together, the results indicate that the region encompassing the C-terminal portion of the PAS domain harbors a structure(s) capable of repressing nuclear import of the receptor. Since this region directly coincides with the core LBD of the receptor, the results are consistent with a model whereby, in the context of the full-length receptor, the ligand-binding domain is capable of mediating conditional repression on a distant NLS.

To determine whether the nuclear localized, LBD-deficient mutant of the dioxin receptor was transcriptionally active, we next analyzed reporter gene activity by cotransfection with an XRE-driven luciferase reporter gene in CHO cells (Fig. 1C). In control experiments, coexpression of the wild-type dioxin receptor together with Arnt resulted in dioxin-dependent activation of reporter gene activity. To our surprise, however, coexpression of Arnt together with the dioxin receptor deletion mutant DRDelta LBD failed to stimulate reporter gene activity in the presence or absence of dioxin. Thus, whereas deletion of the minimal ligand/hsp90-binding region of the dioxin receptor was sufficient to unmask or derepress the constitutive NLS activity in the bHLH domain of the receptor, the resulting nuclear localized protein failed to function as a ligand-independent transcriptional activator.

DRDelta LBD Is Impaired in Its Ability to Interact with Arnt and Fails to Recognize the XRE Sequence Motif-- The C terminus of the dioxin receptor harbors potent transactivation domains that, when attached to a heterologous DNA-binding domain, can function autonomously, displaying constitutive transcriptional activity (26, 33, 37). In the natural structural context of the intact receptor, however, transcriptional activity requires the presence of ligand, suggesting an additional role for the LBD in regulation of the distant transactivation function (26). Consequently, we wanted to determine whether deletion of the minimal LBD in DRDelta LBD had been sufficient to derepress the potent transcriptional activity inherent in the C terminus of the receptor. To this end, we constructed a fusion protein in which we replaced the N-terminal bHLH motif of DRDelta LBD with the glucocorticoid receptor zinc finger DNA-binding domain (GRDBD/DRDelta LBD). Whereas a reference chimeric receptor, GRDBD/DR (26), containing an intact LBD showed strictly ligand-dependent stimulation of a glucocorticoid response element-driven reporter gene construct in CHO cells, the minimal LBD deletion chimera GRDBD/DRDelta LBD displayed constitutive transcriptional activity that was unaffected by the presence of ligand (Fig. 2A).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Deletion of the minimal LBD of the dioxin receptor derepresses the potent C-terminal transactivation function of the receptor and renders it independent of regulation by hsp90. A, activities of the glucocorticoid receptor/dioxin receptor chimeras in transient transfection assays in mammalian cells. CHO cells were transiently transfected with the glucocorticoid response element (GRE)-driven reporter gene construct p(GRE)2T105LUC together with either GRDBD or the GRDBD/dioxin receptor expression vectors as indicated. Following transfection, cells were treated with either 10 nM TCDD (black bars) or vehicle alone (0.1% Me2SO; shaded bars). The control lanes (CTRL) represent activity from the reporter alone and empty expression vector. Data are from one experiment performed in duplicate and are representative of three independent experiments. B, activities of the GRDBD/dioxin receptor chimeras in yeast cells under conditions of wild-type versus low levels of hsp90 expression. GRDBD and the indicated GRDBD/mouse dioxin receptor chimeras were expressed in yeast together with the reporter gene pUCDelta SS26X under conditions of normal (galactose; GAL) or low (glucose; GLU) hsp90 expression levels in the presence (black bars) or absence (shaded bars) of 10 µM indolo[3,2-b]carbazole and assayed for beta -galactosidase activity. Data are from one experiment performed in duplicate and are representative of three independent experiments. TK, thymidine kinase; CYC1, cytochrome c1 promoters, respectively.

A number of biochemical experiments suggest that hsp90 regulates dioxin receptor function by folding the receptor in a high affinity ligand binding conformation (21). This model is strongly supported by yeast (Saccharomyces cerevisiae) genetic experiments that demonstrated that down-regulation of hsp90 expression levels results in a ligand-non-responsive form of the receptor (20, 22). Importantly, consistent with the deletion of the hsp90-binding region overlapping with the ligand binding function of the dioxin receptor, the transcriptional activity of the chimeric GRDBD/DRDelta LBD protein was unaffected by changes in the level of hsp90 in yeast cells (Fig. 2B). Taken together, our results indicate that deletion of the minimal domain harboring both the ligand- and hsp90-binding activities of the receptor efficiently derepresses the potent constitutive C-terminal transactivation function in DRDelta LBD and renders the transactivation function of the dioxin receptor independent of regulation by hsp90.

Given the inability of DRDelta LBD to function on an XRE-driven reporter gene, we next examined whether the protein was deficient in its ability to dimerize with Arnt or to bind DNA. To this end, we expressed the wild-type dioxin receptor, DRDelta LBD, and Arnt by in vitro translation in rabbit reticulocyte lysate. In control experiments, we monitored wild-type dioxin receptor/Arnt dimerization activity by incubating the [35S]methionine-labeled dioxin receptor with an equal concentration of unlabeled Arnt in the presence or absence of ligand, followed by immunoprecipitation using polyclonal anti-Arnt antibodies. As expected, we observed ligand-dependent interaction between the wild-type receptor and Arnt (Fig. 3B, compare lanes 2 and 3). In contrast, however, DRDelta LBD failed to form a stable complex with Arnt in the presence or absence of ligand since only low levels of nonspecific interaction were demonstrated by the co-immunoprecipitation assay (Fig. 3B, compare lanes 5 and 6). In excellent agreement with its impaired ability to interact with Arnt, DRDelta LBD failed to bind the XRE sequence motif in gel mobility shift experiments (Fig. 3C). In conclusion, these results suggest that deletion of the minimal LBD of the dioxin receptor strongly impairs the ability of the receptor to recruit Arnt and thus form a DNA-binding complex, possibly due to induction of conformational changes within the deletion mutant.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   DRDelta LBD is impaired in its ability to interact with Arnt and fails to recognize the XRE sequence motif. A, shown are the results from the analysis of the in vitro translated, [35S]methionine-labeled wild-type dioxin receptor or the dioxin receptor deletion mutant DRDelta LBD. The positions of protein mass markers are shown on the left. B, the deletion of the minimal LBD of the dioxin receptor abrogated dimerization activity with Arnt. Equal concentrations of the in vitro translated, [35S]methionine-labeled dioxin receptor or DRDelta LBD were incubated with unlabeled Arnt in the presence (lanes 1, 2, 4, and 5) or absence (lanes 3 and 6) of 10 nM TCDD as indicated. Co-immunoprecipitation was carried out with Arnt-specific antiserum (S; lanes 2, 3, 5, and 6) or preimmune control serum (C; lanes 1 and 4). The resulting co-immunoprecipitated products were visualized by SDS-PAGE and fluorography. C, in vitro translated, unlabeled Arnt (lane 1), the dioxin receptor (lane 2), the dioxin receptor deletion mutant DRDelta LBD (lanes 5 and 6), or mixtures of Arnt and the dioxin receptor (lanes 3 and 4) or DRDelta LBD (lanes 7 and 8) were incubated with 10 nM TCDD or vehicle alone (0.1% Me2SO) for 2 h at 25 °C. DNA-binding activity was assessed by a gel mobility shift assay using a 32P-labeled XRE oligonucleotide probe. The positions of free probe (Free) and the dioxin receptor-Arnt complex (DR/Arnt) are indicated.

Definition of a Dioxin Receptor Deletion Mutant That Shows Both Constitutive Dimerization Activity with Arnt and Constitutive Interaction with the XRE Sequence Motif-- In addition to harboring the minimal ligand- and hsp90-binding activities, the PAS domain of the dioxin receptor has also been shown to mediate a number of additional receptor activities. We have previously demonstrated that the PAS domain of the dioxin receptor can function as a dimerization interface independently of the bHLH domain in a hybrid-protein interaction assay in mammalian cells (15). Furthermore, the C-terminal half of the PAS domain located between amino acids 230 and 421 and containing the minimal LBD spanning the PAS B motif has been shown to be essential for the PAS-mediated interaction with Arnt (15). We therefore examined the dimerization and DNA-binding activities of the dioxin receptor deletion mutant DRDelta PASB, lacking the minimal PAS B motif encompassed by amino acids 288-421, but maintaining the N-terminal half of the LBD including the PAS A motif (Fig. 4A). Using in vitro translated proteins together with the Arnt co-immunoprecipitation assay, we first tested the ability of DRDelta PASB to dimerize in vitro with Arnt. In contrast to the wild-type dioxin receptor, which displayed ligand-dependent interaction with Arnt (Fig. 4C, lanes 1 and 2) the minimal PAS B deletion mutant (DRDelta PASB) showed constitutive dimerization activity that was unaffected by the presence of ligand (lanes 3 and 4). Moreover, this mutant displayed far more potent dimerization activity than the ligand-induced wild-type receptor (Fig. 4C, compare lanes 2-4). In gel mobility shift experiments, DRDelta PASB bound the XRE motif together with Arnt independently of the presence of ligand (Fig. 4D, compare lanes 2 and 3). These results demonstrate that additional sequences N-terminal of the minimal PAS B motif incorporating the N-terminal half of the LBD are sufficient to reconstitute dimerization and DNA-binding activity between the dioxin receptor and Arnt. Since, in contrast to the wild-type dioxin receptor, DRDelta PASB was able to bind Arnt in a ligand-independent manner, the results also suggest that deletion of the minimal PAS B motif may be sufficient to generate a conformational change in the bHLH domain of the receptor to form a surface competent of interacting with Arnt independently of ligand binding.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 4.   DRDelta PASB shows both constitutive dimerization activity with Arnt and constitutive interaction with the XRE sequence motif. A, shown is a schematic representation of the full-length mouse dioxin receptor (mDR) and the dioxin receptor deletion mutant lacking the C-terminal half of the minimal LBD (termed DRDelta PASB). B, shown are the results from the analysis of the in vitro translated, [35S]methionine-labeled wild-type dioxin receptor or the dioxin receptor deletion mutant DRDelta PASB. The positions of protein mass markers are shown on the left. C, equal concentrations of the in vitro translated, [35S]methionine dioxin receptor or DRDelta PASB were incubated with an equal concentration of unlabeled Arnt in the presence or absence of 10 nM TCDD as indicated. Co-immunoprecipitation was carried out with Arnt-specific antiserum, and the resulting co-immunoprecipitated products were visualized by SDS-PAGE and fluorography. D, in vitro translated, unlabeled DRDelta PASB (lane 1) or DRDelta PASB together with an equal concentration of unlabeled Arnt (lanes 2-6) was incubated for 2 h at 25 °C in the absence (lanes 1, 2, and 4-6) or presence (lane 3) of specific ligand. DNA-binding activity was assessed by a gel mobility shift assay using a 32P-labeled XRE probe. Specificity of DNA-binding complexes was analyzed by incubation with receptor-specific (alpha DR; lane 4), Arnt-specific (alpha Arnt; lane 5), or preimmune (P.I.S.; lane 6) serum. The positions of free probe (Free), the dioxin receptor deletion mutant-Arnt complex (DRDelta PASB/Arnt), and a supershifted complex (SS) are indicated.

Potent Constitutive Functional Activity of the Dioxin Receptor Deletion Mutant Lacking the Minimal PAS B Motif-- We next examined the functional activity of DRDelta PASB together with Arnt in transient transfection assays using the XRE-driven luciferase reporter gene construct. Although DRDelta PASB contained an N-terminal portion of the ligand/hsp90-binding domain, in vitro translated DRDelta PASB was unable to bind ligand in vitro (Fig. 5A). In addition, DRDelta PASB maintained the ability to transactivate in a ligand- and hsp90-independent manner as a GRDBD chimera in yeast cells (Fig. 5B), indicating that extension of the PAS domain to incorporate the N-terminal half of the minimal LBD did not impair the functional activity of the C-terminal transactivation domain. Moreover, it did not repress the ability of a GFP-DRDelta PASB fusion protein to localize constitutively to the nucleus (Fig. 5C) (36).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Characterization of the dioxin receptor deletion mutant DRDelta PASB. A, shown is ligand-binding activity. Unprogrammed rabbit reticulocyte lysate (control (CTRL)) or lysate containing equal concentrations of the in vitro translated, full-length dioxin receptor or the dioxin receptor deletion mutant DRDelta PASB was incubated with 1 nM [3H]TCDD for 90 min at 25 °C and then adsorbed to hydroxylapatite for 30 min at 4 °C. After extensive washing, bound [3H]TCDD was determined by scintillation counting. Specificity of the binding reaction was assessed by competition with a 150-fold molar excess of unlabeled ligand (tetrachlorodibenzofuran) as indicated. B, the activity of the GRDBD/DRDelta PASB chimera was unaffected under conditions of low hsp90 expression in yeast cells. GRDBD and the GRDBD/DRDelta PASB chimera were expressed in yeast under conditions of normal (galactose; GAL) or low (glucose; GLU) hsp90 expression levels in the presence (black bars) or absence (shaded bars) of 10 µM indolo[3,2-b]carbazole and assayed for beta -galactosidase activity. Data represent average values from two samples assayed in a given experiment. C, CHO cells grown on glass coverslips were transfected with 1 µg of expression plasmid for GFP-DRDelta PASB. Twenty-four hours after transfection, the cells were treated with 10 nM TCDD or vehicle (Me2SO) for 2 h as indicated. The cells were then washed with PBS and fixed with 4% paraformaldehyde. The localization of GFP-DRDelta PASB fusion protein was observed as described in the legend to Fig. 1B, and representative images are shown. The experiments were repeated at least three times with similar results. Original magnification was ×400.

In contrast to the wild-type dioxin receptor, DRDelta PASB strongly stimulated XRE-driven reporter gene activity upon coexpression with Arnt in CHO cells in the absence of ligand (Fig. 6A). Thus, in the natural structural context of the intact receptor, the PAS B motif is the critical determinant to maintain the receptor in a transcriptionally inactive state. Furthermore, the observed reporter gene activity was unaffected by the presence of ligand, demonstrating that this dioxin receptor deletion mutant functioned as a constitutively active regulatory protein. To our surprise, however, the constitutive activity of DRDelta PASB was found to be more potent than that produced by the wild-type receptor exposed to a maximally inducing dose of dioxin (Fig. 6A). In these experiments, the wild-type dioxin receptor and the dioxin receptor deletion mutant were expressed at similar levels (Fig. 6B). Potent transactivation was observed in a number of different cell lines, including human cervical adenocarcinoma HeLa and mouse adrenal Y1 cells (Fig. 6C) (data not shown).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 6.   Constitutive activity of DRDelta PASB in mammalian cells. A and C, CHO and HeLa cells, respectively, were transiently transfected with the XRE-driven luciferase reporter gene pTX.DIR together with the either wild-type dioxin receptor or the dioxin receptor deletion mutant DRDelta PASB and Arnt. Following transfection, cells were treated with 10 nM TCDD (black bars) or vehicle alone (0.1% Me2SO; shaded bars) as indicated. Data are presented as luciferase activity relative to cells transfected with empty expression vector and reporter gene alone (control (CTRL)) in the absence of ligand. Values represent the mean ± S.E. of three independent experiments performed in duplicate. B, shown is the detection of the wild-type dioxin receptor or the dioxin receptor deletion mutant DRDelta PASB following transient expression in CHO cells. Whole cell extracts (30 µg of protein) were separated by 7.5% SDS-PAGE and transferred to nitrocellulose membrane, and the relative expression levels of the full-length dioxin receptor (lane 2) and DRDelta PASB (lane 3) were determined by immunodetection with monoclonal anti-FLAG antibody, followed by chemiluminescence. Lane 1 represents whole cell extracts from untransfected cells. The positions of protein mass markers are shown on the left.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transcription factors are generally acknowledged to have a modular structure. In the case of the dioxin receptor, the receptor is composed of a number of domains that harbor distinct separable functions, including N-terminal DNA-binding and dimerization domains and a C-terminal transactivation domain. Ligand binding by the dioxin receptor is an independent property of the centrally located LBD encompassing amino acids 230-421 and spanning the C-terminal half of the PAS domain. Moreover, this minimal LBD of the dioxin receptor has been shown to be transferable, retaining its activity when attached to other proteins, supporting the view that receptor LBDs are independent entities containing all the information necessary for ligand binding (19). In addition to being a critical determinant of ligand-binding activity, the LBD of the dioxin receptor has also been postulated to function in the repression of receptor function in the absence of ligand (19). Similarly, in the absence of specific agonist, the LBD of the glucocorticoid receptor functions in the repression of a number of receptor activities, including nuclear localization, dimerization, DNA binding, and transactivation. Exposure to agonist ligand induces nuclear import and results in derepression of receptor function (38, 39). Thus, within the normal context of the intact receptor, the LBD specifies a reversible inactivation function that, in the absence of ligand, inhibits other receptor activities. In this study, we have demonstrated that deletion of the minimal LBD of the dioxin receptor results in a protein that is constitutively localized to the nucleus. In striking contrast to steroid receptors, however, this nuclear localized, LBD-deficient mutant of the receptor was functionally inert in reporter gene assays in the presence and absence of ligand. Further analysis revealed that, although the C-terminal transactivation function had been efficiently derepressed, this receptor deletion mutant had lost the ability to dimerize with Arnt, thus rendering it incapable of forming an active DNA-binding complex. Inclusion of the N-terminal amino acids of the minimal delineated LBD to the border of the PAS B motif reconstituted dimerization and DNA-binding activity with Arnt. Moreover, the presence of the N-terminal half of the LBD did not impair either the N-terminal NLS activity or the functional activity of the C-terminal transactivation domain of the receptor, indicating that this region is not required for repression of these receptor activities. Furthermore, the receptor was now converted into a constitutive transcriptional activator. Thus, whereas the entire LBD of the glucocorticoid receptor appears to regulate all of these receptor activities, our results suggest that the C-terminal half of the minimal delineated LBD of the dioxin receptor incorporating the PAS B motif is both sufficient and required to maintain the receptor in a transcriptionally inactive state in the absence of ligand.

Previous studies have clearly defined the minimal sequence of the LBD of the dioxin receptor with wild-type ligand binding affinity as extending from amino acids 230 to 421 (21). Moreover, this region of the receptor has also been shown to modulate interaction with the molecular chaperone hsp90, consistent with its role in the folding of a high affinity ligand binding conformation of the receptor (20-22). In this study, we have observed that deletion of the C-terminal half of the LBD incorporating the PAS B motif abolished ligand binding, revealing the critical nature of the residues between amino acids 288 and 421 for ligand-binding activity. Interestingly, this dioxin receptor deletion mutant had also lost the ability to associate with hsp90 in vitro, suggesting that the region spanning the C-terminal half of the minimal LBD incorporating the PAS B motif is the target for regulation by hsp90. In support of this model, the activity of this dioxin receptor deletion mutant was unaffected by reduced levels of hsp90 in the yeast model system. We propose therefore that, in addition to modulating repression of receptor function in the absence of ligand, this region of the receptor may also be required for the folding of the entire delineated LBD to give the native tertiary structure that is optimal for high affinity ligand binding possibly by association with hsp90.

In summary, we have identified the domain of the dioxin receptor that determines repression of receptor function to be the C-terminal 134 amino acids of the LBD. In addition, our results indicate that this region of the receptor is the target for regulation by hsp90. Furthermore, deletion of this domain converts the receptor into a constitutive transcriptional activator. In conclusion, the constitutively active dioxin receptor may provide an important mechanistic tool to investigate receptor-mediated regulatory pathways in closer detail.

    ACKNOWLEDGEMENT

We thank Amina Ossoinak for excellent technical assistance.

    FOOTNOTES

* This work was supported by grants from the Swedish Cancer Society, the European Union, and the NOVARTIS Foundation (Japan) for the Promotion of Science.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed. Tel.: 46-8-728-7330; Fax: 46-8-34-88-19; E-mail: lorenz.poellinger@cmb.ki.se.

Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M105607200

    ABBREVIATIONS

The abbreviations used are: TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; hsp90, 90-kDa heat shock protein; bHLH, basic helix-loop-helix; LBD, ligand-binding domain; XRE, xenobiotic response element; DR, dioxin receptor; GRDBD, glucocorticoid receptor zinc finger DNA-binding domain; PCR, polymerase chain reaction; GFP, green fluorescent protein; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; NLS, nuclear localization signal.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Gu, Y. Z., Hogenesch, J. B., and Bradfield, C. A. (2000) Annu. Rev. Pharmacol. Toxicol. 40, 519-561[CrossRef][Medline] [Order article via Infotrieve]
2. Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., and Gonzalez, F. J. (1995) Science 268, 722-726[Abstract/Free Full Text]
3. Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., and Bradfield, C. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6731-6736[Abstract/Free Full Text]
4. Mimura, J., Yamashita, K., Nakamura, K., Morita, M., Takagi, T. N., Nakao, K., Ema, M., Sogawa, K., Yasuda, M., Katsuki, M., and Fujii-Kuriyama, Y. (1997) Genes Cells 2, 645-654[Abstract]
5. Lahvis, G. P., Lindell, S. L., Thomas, R. S., McCuskey, R. S., Murphy, C., Glover, E., Bentz, M., Southard, J., and Bradfield, C. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10442-10447[Abstract/Free Full Text]
6. Perdew, G. H. (1992) Biochem. Biophys. Res. Commun. 182, 55-62[CrossRef][Medline] [Order article via Infotrieve]
7. Chen, H. S., and Perdew, G. H. (1994) J. Biol. Chem. 269, 27554-27558[Abstract/Free Full Text]
8. Carver, L. A., and Bradfield, C. A. (1997) J. Biol. Chem. 272, 11452-11456[Abstract/Free Full Text]
9. Ma, Q., and Whitlock, J. P. (1997) J. Biol. Chem. 272, 8878-8884[Abstract/Free Full Text]
10. Meyer, B. K., Pray-Grant, M. G., Vanden Heuvel, J. P., and Perdew, G. H. (1998) Mol. Cell. Biol. 18, 978-988[Abstract/Free Full Text]
11. Kazlauskas, A., Poellinger, L., and Pongratz, I. (1999) J. Biol. Chem. 274, 13519-13524[Abstract/Free Full Text]
12. Crews, S. T. (1998) Genes Dev. 12, 607-620[Free Full Text]
13. Taylor, B. L., and Zhulin, I. B. (1999) Microbiol. Mol. Biol. Rev. 63, 479-506[Abstract/Free Full Text]
14. Huang, Z. J., Edery, I., and Rosbash, M. (1993) Nature 364, 259-262[CrossRef][Medline] [Order article via Infotrieve]
15. Lindebro, M. C., Poellinger, L., and Whitelaw, M. L. (1995) EMBO J. 14, 3528-3539[Medline] [Order article via Infotrieve]
16. Pongratz, I., Antonsson, C., Whitelaw, M. L., and Poellinger, L. (1998) Mol. Cell. Biol. 18, 4079-4088[Abstract/Free Full Text]
17. Zelzer, E., Wappner, P., and Shilo, B. Z. (1997) Genes Dev. 11, 2079-2089[Abstract/Free Full Text]
18. Burbach, K. M., Poland, A., and Bradfield, C. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8185-8189[Abstract/Free Full Text]
19. Whitelaw, M. L., Gottlicher, M., Gustafsson, J. Å., and Poellinger, L. (1993) EMBO J. 12, 4169-4179[Medline] [Order article via Infotrieve]
20. Carver, L. A., Jackiw, V., and Bradfield, C. A. (1994) J. Biol. Chem. 269, 30109-30112[Abstract/Free Full Text]
21. Coumailleau, P., Poellinger, L., Gustafsson, J. Å., and Whitelaw, M. L. (1995) J. Biol. Chem. 270, 25291-25300[Abstract/Free Full Text]
22. Whitelaw, M. L., McGuire, J., Picard, D., Gustafsson, J. Å., and Poellinger, L. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4437-4441[Abstract/Free Full Text]
23. McGuire, J., Whitelaw, M. L., Pongratz, I., Gustafsson, J. Å., and Poellinger, L. (1994) Mol. Cell. Biol. 14, 2438-2446[Abstract/Free Full Text]
24. Mason, G. G., Witte, A. M., Whitelaw, M. L., Antonsson, C., McGuire, J., Wilhelmsson, A., Poellinger, L., and Gustafsson, J. Å. (1994) J. Biol. Chem. 269, 4438-4449[Abstract/Free Full Text]
25. Kallio, P. J., Okamoto, K., O'Brien, S., Carrero, P., Makino, Y., Tanaka, H., and Poellinger, L. (1998) EMBO J. 17, 6573-6586[CrossRef][Medline] [Order article via Infotrieve]
26. Whitelaw, M. L., Gustafsson, J. Å., and Poellinger, L. (1994) Mol. Cell. Biol. 14, 8343-8355[Abstract/Free Full Text]
27. Berghard, A., Gradin, K., Pongratz, I., Whitelaw, M., and Poellinger, L. (1993) Mol. Cell. Biol. 13, 677-689[Abstract/Free Full Text]
28. Gradin, K., Whitelaw, M. L., Toftgård, R., Poellinger, L., and Berghard, A. (1994) J. Biol. Chem. 269, 23800-23807[Abstract/Free Full Text]
29. Picard, D., Khursheed, B., Garabedian, M. J., Fortin, M. G., Lindquist, S., and Yamamoto, K. R. (1990) Nature 348, 166-168[CrossRef][Medline] [Order article via Infotrieve]
30. Gietz, D., St. Jean, A., Woods, R. A., and Schiestl, R. H. (1992) Nucleic Acids Res. 20, 1425[Free Full Text]
31. Antonsson, C., Whitelaw, M. L., McGuire, J., Gustafsson, J. Å., and Poellinger, L. (1995) Mol. Cell. Biol. 15, 756-765[Abstract]
32. Cuthill, S., Wilhelmsson, A., and Poellinger, L. (1991) Mol. Cell. Biol. 11, 401-411[Abstract/Free Full Text]
33. Ma, Q., Dong, L., and Whitlock, J. P. (1995) J. Biol. Chem. 270, 12697-12703[Abstract/Free Full Text]
34. Ikuta, T., Eguchi, H., Tachibana, T., Yoneda, Y., and Kawajiri, K. (1998) J. Biol. Chem. 273, 2895-2904[Abstract/Free Full Text]
35. Kazlauskas, A., Poellinger, L., and Pongratz, I. (2000) J. Biol. Chem. 275, 41317-41324[Abstract/Free Full Text]
36. Kazlauskas, A., Sundström, S., Poellinger, L., and Pongratz, I. (2001) Mol. Cell. Biol. 21, 2594-2607[Abstract/Free Full Text]
37. Jain, S., Dolwick, K. M., Schmidt, J. V., and Bradfield, C. A. (1994) J. Biol. Chem. 269, 31518-31524[Abstract/Free Full Text]
38. Yamamoto, K. R., Godowski, P. J., and Picard, D. (1988) Cold Spring Harbor Symp. Quant. Biol. 53, 803-811
39. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) Cell 83, 835-839[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Circ. Res.Home page
P. Dabir, T. E. Marinic, I. Krukovets, and O. I. Stenina
Aryl Hydrocarbon Receptor Is Activated by Glucose and Regulates the Thrombospondin-1 Gene Promoter in Endothelial Cells
Circ. Res., June 20, 2008; 102(12): 1558 - 1565.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. R. Evans, S. I. Karchner, L. L. Allan, R. S. Pollenz, R. L. Tanguay, M. J. Jenny, D. H. Sherr, and M. E. Hahn
Repression of Aryl Hydrocarbon Receptor (AHR) Signaling by AHR Repressor: Role of DNA Binding and Competition for AHR Nuclear Translocator
Mol. Pharmaco